Neumora Therapeutics is trading at $0.39, down 10.15%. The available evidence does not identify a clear direct catalyst for the October 13 decline.
- An October 13 report says Wall Street Zen lowered its rating to Strong Sell, but does not establish that the downgrade caused the drop.
- Biotech-sector weakness may be additional context: supplied sector data has XBI down 2.01%, while broader major indices are only modestly lower.